FDA Approves Xocova: A New Post-Exposure Pill to Prevent COVID-19
The FDA has approved Xocova, a new oral medication designed to prevent COVID-19 infection after direct exposure. Available for individuals aged 12 and older, the drug significantly reduces the risk of contracting the virus if taken within three days of contact with an infected person. While it offers a new layer of protection, experts emphasize that it is not a substitute for vaccination and is intended for specific high-risk exposure scenarios rather than general preventive use.